We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+34.6%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$555M
AUM Growth
-$203M
Cap. Flow
-$287M
Cap. Flow %
-51.67%
Top 10 Hldgs %
64.54%
Holding
90
New
25
Increased
22
Reduced
13
Closed
18

Top Buys

Rank Stock Value
1
THER
THERATECHNOLOGIES INC COM
THER
+$26.9M
2
KRYS icon
Krystal Biotech
KRYS
+$11.4M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$10.8M
4
AZN icon
AstraZeneca
AZN
+$9.76M
5
CCCC icon
C4 Therapeutics
CCCC
+$7.78M

Top Sells

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$10.2M
2
VCEL icon
Vericel Corp
VCEL
+$7.3M
3
EPIX
ESSA Pharma
EPIX
+$7.1M
4
MRSN
Mersana Therapeutics
MRSN
+$5.5M
5
DRIO icon
DarioHealth
DRIO
+$5.02M

Sector Composition

Rank Sector Weight
1 Healthcare 90.73%
2 Consumer Staples 1.79%
3 Real Estate 0.62%
4 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCAB icon
1
BioAtla
BCAB
$5.59M
$162M 29.12%
63,587
– –
EPIX
2
DELISTED
ESSA Pharma
EPIX
$60.1M 10.84%
2,070,052
-305,629
-13% -$7.1M
THER
3
DELISTED
THERATECHNOLOGIES INC COM
THER
$26.9M 4.84%
+6,951,347
New +$26.9M
ISEE
4
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$20.9M 3.76%
3,380,979
+1,783,700
+112% +$10.8M
LNTH icon
5
Lantheus
LNTH
$6.82B
$20.7M 3.72%
967,372
+225,287
+30% +$4.09M
CCCC icon
6
C4 Therapeutics
CCCC
$376M
$17.2M 3.09%
464,068
+195,520
+73% +$7.78M
KRYS icon
7
Krystal Biotech
KRYS
$9.88B
$12.9M 2.32%
166,844
+156,421
+1,501% +$11.4M
AZN icon
8
AstraZeneca
AZN
$263B
$12.8M 2.32%
129,223
+97,081
+302% +$9.76M
XENE icon
9
Xenon Pharmaceuticals
XENE
$6.32B
$12.7M 2.28%
708,117
+150,000
+27% +$2.54M
IRMD icon
10
iRadimed
IRMD
$1.21B
$12.4M 2.24%
482,070
+178,072
+59% +$4.25M
SKIN icon
11
SkinHealth Systems
SKIN
$94.9M
$9.94M 1.79%
920,716
+504,165
+121% +$5.54M
DMRA
12
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.77B
$9.19M 1.66%
60,506
– –
SRDX
13
DELISTED
Surmodics
SRDX
$8.65M 1.56%
154,275
+61,300
+66% +$3.06M
INBX
14
DELISTED
Inhibrx, Inc. Common Stock
INBX
$8.06M 1.45%
401,493
+187,686
+88% +$5.48M
NTRA icon
15
Natera
NTRA
$37.5B
$7.94M 1.43%
78,239
+4,050
+5% +$444K
ITMR
16
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$6.47M 1.17%
270,080
+129,556
+92% +$3.08M
MSON
17
DELISTED
Misonix Inc
MSON
$5.9M 1.06%
301,333
– –
PCVX icon
18
Vaxcyte
PCVX
$7.89B
$5.8M 1.05%
+293,650
New +$7.39M
LYRA
19
DELISTED
LYRA THERAPEUTICS INC
LYRA
$5.51M 0.99%
9,516
+393
+4% +$246K
ASMB icon
20
Assembly Biosciences
ASMB
$506M
$5.16M 0.93%
+93,500
New +$6.2M
MDXG icon
21
MiMedx Group
MDXG
$626M
$5.15M 0.93%
+500,000
New +$4.83M
FLXN
22
DELISTED
Flexion Therapeutics, Inc.
FLXN
$4.68M 0.84%
+522,500
New +$5.99M
SPRY icon
23
ARS Pharmaceuticals
SPRY
$590M
$4.24M 0.76%
97,256
-10,570
-10% -$500K
EXEL icon
24
Exelixis
EXEL
$13.9B
$4.12M 0.74%
182,347
-208,500
-53% -$4.71M
RPTX
25
DELISTED
Repare Therapeutics
RPTX
$4.09M 0.74%
+133,324
New +$4.53M
1
2 3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Soleus Capital Management held 90 positions worth $555M, down 27% from $758M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Soleus Capital Management withdrew a net $287M in Q1 2021, closing 18 positions and reducing 13 holdings. Its most notable exit was Invitae Corporation, an estimated $10.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 44% a quarter earlier, followed by Consumer Staples and Real Estate.

Against the trend, Soleus Capital Management opened a new position in THERATECHNOLOGIES INC COM worth $26.9M.

  • Soleus Capital Management's largest Q1 2021 buy was THERATECHNOLOGIES INC COM: 6,951,347 shares worth $26.9M.
  • Soleus Capital Management added most to Krystal Biotech in Q1 2021, an estimated $11.4M increase.
  • Soleus Capital Management's biggest Q1 2021 reduction was ESSA Pharma, cutting an estimated $7.1M.
  • Soleus Capital Management fully exited Invitae Corporation in Q1 2021, selling an estimated $10.2M.
  • Soleus Capital Management's ten largest holdings make up 65% of its $555M portfolio in Q1 2021.
  • Soleus Capital Management opened 25 new positions and closed 18 in Q1 2021.
  • Soleus Capital Management's portfolio value fell 27% quarter-over-quarter to $555M.

Based on Soleus Capital Management's 13F filing for Q1 2021, filed 17 May 2021.